Difficulty in Repurposing Selective Serotonin Reuptake Inhibitors and Other Antidepressants with Functional Inhibition of Acid Sphingomyelinase in COVID-19 Infection

@article{LeCorre2022DifficultyIR,
  title={Difficulty in Repurposing Selective Serotonin Reuptake Inhibitors and Other Antidepressants with Functional Inhibition of Acid Sphingomyelinase in COVID-19 Infection},
  author={Pascal Le Corre and Gwenol{\'e} Loas},
  journal={Frontiers in Pharmacology},
  year={2022},
  volume={13}
}
The rapid spread of COVID-19 has become a health emergency causing an urgent need for drug treatments to control the outbreak, especially in more vulnerable individuals. This is reinforced by the fact that prophylactic vaccines and neutralizing monoclonal antibodies may not be fully effective against emerging variants. Despite all efforts made by the scientific community, efficient therapeutic options currently remain scarce, either in the initial, as well as in the advanced forms of the… 
2 Citations
COVID-19-Current Therapeutical Approaches and Future Perspectives
TLDR
This review focuses on the current and new therapeutical approaches, summarizing the viral structure and life cycle, with an emphasis on the specific steps that can be interfered by antivirals.
Association of Amlodipine with the Risk of In-Hospital Death in Patients with COVID-19 and Hypertension: A Reanalysis on 184 COVID-19 Patients with Hypertension
TLDR
The result of the present study suggests that amlodipine may be associated with reduced mortality in people with hypertension infected with COVID-19, and further research and randomized clinical trials are needed to confirm the potential protective effect.

References

SHOWING 1-10 OF 58 REFERENCES
Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?
  • Yaser Pashaei
  • Biology, Medicine
    Journal of Clinical Neuroscience
  • 2021
Mechanisms of action of fluvoxamine for COVID-19: a historical review
TLDR
A possible link between maternal COVID-19 infection and a risk for neuropsychiatric disorders and schizophrenia in offspring is discussed and fluvoxamine is the most attractive drug for mild to moderate subjects with CO VID-19.
Fluvoxamine and amantadine: central nervous system acting drugs repositioned for COVID-19 as early intervention.
TLDR
Preclinical and early clinical evidence is presented indicating that fluvoxamine and amantadine hold promise to prevent COVID-19 progression when administered early during infection.
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence
TLDR
Fluvoxamine appears to have substantial potential as a safe and widely available medication that could be repurposed to ameliorate serious COVID-19-related morbidity and mortality.
Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine
TLDR
Fluoxetine, a widely used antidepressant and a functional inhibitor of acid sphingomyelinase (FIASMA), efficiently inhibited the entry and propagation of SARS-CoV-2 in the cell culture model without cytotoxic effects and also exerted potent antiviral activity against two currently circulating influenza A virus subtypes.
Pharmacologically induced endolysosomal cholesterol imbalance through clinically licensed drugs itraconazole and fluoxetine impairs Ebola virus infection in vitro
TLDR
It is provided evidence that cholesterol imbalance is a conserved cross-species mechanism to hamper EBOV infection and exploring the endolysosomal host–pathogen interface as a suitable antiviral treatment may offer a general strategy to combat EBOv infection.
Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection
TLDR
An update of knowledge about the interest of the functional inhibitors of acid sphingomyelinase (FIASMAs) in SARS-CoV-2 infection is presented.
Are central nervous system drugs displaying anti-inflammatory activity suitable for early treatment of COVID-19?
TLDR
In two small controlled clinical trials, early treatment of SARS-CoV-2-infected persons with fluvoxamine fully prevented COVID-19 symptoms and anecdotal evidence shows that amantadine may be similarly effective.
Fluoxetine Is a Potent Inhibitor of Coxsackievirus Replication
TLDR
Molecular screening of small molecule libraries identified fluoxetine, a selective serotonin reuptake inhibitor, as a potent inhibitor of coxsackievirus replication and it was found that it markedly reduced the synthesis of viral RNA and protein.
Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS‐CoV‐2 infection in vitro
TLDR
The therapeutic potential of targeting the interface of SARS CoV‐2 with the host via repurposing of clinically licensed drugs and their use in combinatory treatments with virus‐ and host‐directed drugs in vitro is investigated.
...
...